HEART UK consensus statement on Lipoprotein(a): A call to action.

Area of Science:

• Cardiology
• Genetics
• Lipidology

Background:

• Lipoprotein(a) (Lp(a)) is an atherogenic particle with high heritability.
• Elevated Lp(a) levels are a significant, independent risk factor for cardiovascular disease (CVD).

Purpose of the Study:

• To provide evidence-based recommendations for measuring Lp(a) in clinical practice.
• To review current and emerging therapeutic strategies for reducing CVD risk in individuals with high Lp(a).

Main Methods:

• Consensus statement development by HEART UK based on existing evidence.
• Identification of specific adult populations recommended for Lp(a) measurement.
• Review of therapeutic strategies including risk reduction and lipoprotein apheresis.

Main Results:

• Recommends Lp(a) measurement in adults with premature atherosclerotic CVD history, family history of high Lp(a), familial hypercholesterolemia, calcific aortic valve stenosis, or borderline CVD risk.
• Highlights the importance of reducing overall atherosclerotic risk and controlling dyslipidemia (non-HDL-cholesterol <100 mg/dL).

Conclusions:

• Lp(a) measurement is recommended for specific at-risk adult populations.
• Management strategies involve comprehensive cardiovascular risk reduction and consideration of advanced therapies like lipoprotein apheresis.